NEW YORK, Oct. 10 - GlaxoSmithKline and First Genetic Trust have entered into a broad SNP-related research collaboration to define why some individuals are susceptible to certain serious adverse events, the companies said on Wednesday.
GlaxoSmithKline will sponsor the study and conduct all analyses, while First Genetic Trust will provide its independent secure genetic banking services to store biological samples and medical data.
First Genetic Trust will also ensure that participating patients’ privacy is protected.
“Pharmacogenetic studies such as this one will not only increase patient safety but also provide a scientific basis to understand ADRs at the molecular level,'' Allen Roses, senior vice president of genetics research at GlaxoSmithKline, said in a statement.
“We expect the collaboration to … contribute to the refinement of our genetic banking services that are available to the clinical research community,” added Arthur Holden, chairman, CEO, and co-founder of First Genetic Trust.
This announcement comes exactly one year after a team of leading researchers from the SNP Consortium, Motorola, and IBM said they planned to create a new company-- now known as First Genetic Trust --to serve as a genetic bank that will hold individual genetic profiles and act as an intermediary between patients, researchers, and healthcare providers.